Hansa Biopharma (Q1 Initial take): Soft Q1, as Expected - Redeye

Redeye provides its first take on Hansa Biopharma's Q1 report. Revenues were SEK35m in the quarter, a decline Q/Q and Y/Y and lower than our forecast. Although this was likely expected, we expect a negative share price reaction when the market opens.

Länk till analysen i sin helhet: https://www.redeye.se/research/1160767/hansa-biopharma-q1-initial-take-soft-q1-as-expected?utm_source=finwire&utm_medium=RSS